An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant

NCT02285647 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

138

Enrollment

INDUSTRY

Sponsor class

Conditions

Chemotherapy-induced Nausea and Vomiting

Interventions

DRUG: Rolapitant - Oral
DRUG: Rolapitant - IV

Sponsor

Tesaro, Inc.